Given the evidence suggesting an aberrant AKT/SKP2 pathway in MM and the antiproliferative effect of NSP‐B, it is plausible to hypothesize that NSP‐B may exert its therapeutic effect via the AKT/SKP2 pathway. Here, AKT1 is linked to Miyoshi myopathy.